10-Q: Cannabis Bioscience International Holdings Reports Increased Revenue in Q1 2025, But Remains a Going Concern

Cannabis Bioscience International Holdings, Inc. saw a significant increase in revenue during the first quarter of 2025, primarily driven by growth in clinical trial contracts, but continues to face challenges as a going concern.

Summary

• Cannabis Bioscience International Holdings, Inc. reported its financial results for the quarter ended August 31, 2024.
• The company experienced a substantial increase in revenue, reaching $178,887, compared to $72,821 in the same quarter of the previous year.
• This revenue growth was primarily attributed to a significant rise in clinical trial contracts, which increased from $62,958 to $173,386.
• Despite the revenue increase, the company reported a net loss of $76,305 for the quarter, an improvement from the $181,789 loss in the same period last year.
• The company's operating loss decreased from $176,784 to $97,604 year-over-year.
• A significant non-cash expense of $100,000 was recorded due to the issuance of common stock as compensation.
• If this non-cash expense was excluded, the company would have reported a net income of $26,305 for the quarter.
• The company's cash balance remains low at $969, with a negative working capital of $833,353.
• The company's accumulated deficit is $5,410,385.
• The company's ability to continue as a going concern is still in doubt due to recurring losses and negative cash flows.

Sentiment

Score: 4

Explanation: The document shows some positive signs with increased revenue, but the company's continued losses, low cash balance, and going concern issues create a negative sentiment overall. The need for additional capital and the lack of assurance of obtaining it further contribute to the low score.

Positives

• The company experienced a substantial increase in revenue, primarily from clinical trial contracts.
• The net loss improved significantly compared to the same quarter last year.
• The company recorded a gain of $23,638 from debt forgiveness.
• The operating loss decreased year-over-year.

Negatives

• The company continues to operate with a net loss, despite increased revenue.
• The company has a very low cash balance of $969.
• The company has a significant negative working capital of $833,353.
• The company has a large accumulated deficit of $5,410,385.
• The company's ability to continue as a going concern is still in doubt.
• The company recorded a non-cash expense of $100,000 due to share-based compensation.

Risks

• The company's ability to continue as a going concern is uncertain due to recurring losses and negative cash flows.
• The company needs substantial additional capital to fund its business and repay debts.
• There is no assurance that the company will be able to obtain additional capital on satisfactory terms.
• The company's operations could be materially negatively impacted if adequate capital cannot be obtained.
• The company may be forced to terminate its operations if it cannot secure additional funding.
• The company has significant debt obligations, including EIDL loans and short-term loans, some of which are in arrears.
• The company is dependent on a small number of customers for a large portion of its revenue.

Future Outlook

The company's ability to continue as a going concern depends on the successful execution of its operating plan, which includes expanding its operations and raising either debt or equity financing. There is no assurance that the company will be able to expand its operations or obtain such financing on satisfactory terms or at all.

Management Comments

• The company's management believes that the accompanying unaudited consolidated financial statements contain all the adjustments necessary to present the financial position of the company.
• Management has evaluated all subsequent events when these consolidated financial statements were issued and has determined that none of them requires disclosure herein.

Industry Context

The company operates in the medical cannabis and clinical trials industries, which are both experiencing growth. The company's focus on education and clinical trials positions it to potentially benefit from these trends. However, the company faces competition and regulatory challenges in these sectors.

Comparison to Industry Standards

• The company's revenue growth is a positive sign, but its continued losses and negative working capital are concerning when compared to more established companies in the medical cannabis and clinical trials industries.
• Many companies in the clinical trials sector are able to secure significant funding and achieve profitability, which Cannabis Bioscience International Holdings has not yet demonstrated.
• The company's reliance on a small number of customers is a risk, as is the case with many early-stage companies in these sectors.
• The company's debt levels and ongoing need for capital are also higher than many of its peers.

Management Changes

Related Party Transactions

• The company issued 125,000,000 shares of Common Stock to a related party as compensation for his services as treasurer and a director of the Company.
• The company issued 1,000 shares of Series B Preferred to a related party as compensation for services to be rendered by him in raising capital.
• The company issued 125,000,000 shares of Common Stock to a related party as compensation for his services as secretary the Company.
• The company received cash advances from related parties of $166,918 for use as working capital.
• The company is indebted to related parties for cash advances made by them for use as working capital in the amount of $572,340.

Stakeholder Impact

• Shareholders face significant risk due to the company's financial instability and going concern issues.
• Employees may be impacted by potential layoffs or restructuring if the company cannot secure additional funding.
• Customers may be affected by potential disruptions in services if the company's financial situation worsens.
• Suppliers and creditors face the risk of non-payment if the company's financial situation does not improve.

Next Steps

• The company needs to successfully execute its operating plan, which includes expanding its operations and raising either debt or equity financing.
• The company needs to address its debt obligations and negotiate with creditors to reschedule payments.
• The company needs to continue to grow its revenue and reduce its operating expenses.
• The company needs to secure additional funding to meet its working capital needs.

Key Dates

Keywords

Cannabis Bioscience International Holdings, clinical trials, medical cannabis, revenue, net loss, going concern, debt, share-based compensation, working capital, EIDL loans